quinlash wrote: Zenabis has released their QTR report numbers on schedule. Looks like HEXO scored a great deal on a company that is going to be contributing strong sales in the coming QTR reports.
Good Job HEXO !
Full Year 2020 Highlighted Financial Results
Consolidated net revenue increased 95% to $59.3 million from $30.4 million in 2019;
Gross margin before fair value changes to biological assets and inventories was $24.8 million or 41.8% of net revenue in 2020, compared to $13.7 million or 44.9% of net revenue in the prior year;
Consolidated Adjusted EBITDA for the year totaled $3.5 million, compared to negative $38.7 million in 2019;
Loss from operations of $2.3 million compared to $59.2 million in the prior year;
Consolidated net loss from continuing operations totaled $54.9 million or $0.10 per share, fully diluted, compared to $72.6 million or $0.30 per share, fully diluted, in 2019;
Consolidated net loss for 2020 totaled $70.5 million or $0.13 per share, fully diluted, compared to $127.0 million or $0.53 per share, fully diluted, in 2019;
Loans and borrowing decreased $88.2 million from $153.9 million to $65.7 million;
Net cash used in operations was $17.5 million compared to $78.6 million in 2019.
Link to Summary
https://markets.businessinsider.com/news/stocks/zenabis-announces-full-year-and-fourth-quarter-2020-financial-results-1030266871